Results per Page:
“Exciting” but early results in trial of immunotherapy for myeloma
Cancer cells disappeared rapidly in patients with high-risk, treatment-resistant disease
Fred Hutch at ASH: Combo CAR T-cell therapies, long-term outcomes for CAR T patients, early findings on a CAR T for multiple myeloma, gene therapy for sickle cell, and T cells and the microbiome
The 60th American Society of Hematology Annual Meeting will take place Dec. 1–4 in San Diego
Gene editing shows promise for sickle cell and related disorders
Preclinical results offer new hope in group of dangerous inborn diseases
How the immune system’s key organ regenerates itself
Watch: Hutch researcher discusses harnessing the thymus’s knack for self-repair to boost immune function and help patients
Promising results in trial of engineered T cells in high-risk leukemia
High response rates to experimental immunotherapy in patients with treatment-resistant chronic lymphocytic leukemia
93 percent of advanced leukemia patients in remission after immunotherapy
‘Exciting’ but early results from trial of engineered immune cells